2-(1-naphthyl)-3-methylfuran | 98761-53-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(1-naphthyl)-3-methylfuran
• 英文别名: 3-methyl-2-(1-naphthyl)furan；3-Methyl-2-naphthalen-1-ylfuran
• CAS: 98761-53-6
• 化学式: C₁₅H₁₂O
• 分子量: 208.26
• InChiKey: QVWUKTVYKLIVSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-萘甲醛 在 正丁基锂 、 叔丁基锂 、 草酸 、 silica gel 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-(1-naphthyl)-3-methylfuran
  参考文献：
  名称：

  (E)-1-Bromo-3,3-diethoxy-1-propene (diethyl acetal of 3-bromoacrolein). A versatile synthon for the synthesis of furans, butenolides, and (Z)-allyl alcohols

  摘要：

  DOI：

  10.1021/jo00224a044

文献信息

• Palladium-catalyzed selective decarboxylative coupling reaction versus direct C―H arylation for arylation of heteroaromatics
  作者：Haiyan Fu、Hua Chen、Henri Doucet

  DOI：10.1002/aoc.3037

  日期：2013.10

  Conditions for selective palladium‐catalyzed decarboxylative 2‐arylation of 3‐substituted thiophene and furan derivatives bearing an ester at C2 position have been established. By using 2 mol% phosphine‐free Pd(OAc)2 as the catalyst and a mixture of KOH and K2CO3 as the bases, in dimethylacetamide, moderate to good yields of the desired 2‐arylated products were obtained. A range of functional groups

  建立了选择性取代钯催化的3-取代的噻吩和呋喃衍生物在C2位带有酯的钯催化脱羧2-芳基化的条件。通过在二甲基乙酰胺中使用2 mol％的无膦Pd（OAc）2作为催化剂，并使用KOH和K 2 CO 3的混合物作为碱，可获得中等至良好的所需2-芳基化产物收率。芳基溴化物上的一系列官能团（例如腈，硝基，甲酰基或乙酰基）是可以耐受的。在成本或芳基化的物理性质（沸点）方面，​​这种方法使我们可以在某些情况下采用更方便的反应物。版权所有©2013 John Wiley＆Sons，Ltd.
• MEYERS, A. I.;SPOHN, R. F., J. ORG. CHEM., 1985, 50, N 24, 4872-4877
  作者：MEYERS, A. I.、SPOHN, R. F.

  DOI：——

  日期：——
• COMBINATION PRODUCT FOR THE INDUCTION AND/OR MAINTENANCE OF GENERAL ANESTHESIA
  申请人：BLUMENTECH, S.L.

  公开号：US20210186927A1

  公开（公告）日：2021-06-24

  The state of general anesthesia (GA) is essential to many surgical and medical procedures. This state is characterized by loss of consciousness, deep analgesia and suppression of movements. GA is rarely achieved with a single drug, usually requiring the combination of various pharmacological agents. Each drug can interact with one or more molecular targets affecting neuronal excitability and synaptic transmission in multiple regions of the CNS. Agonists of the μ-opioid receptor are commonly used in GA to cause analgesia, but not to induce or maintain loss of consciousness or movement suppression. Additionally, agonists of the μ-opioid receptor can cause serious unwanted side effects, e.g. respiratory depression. The present invention provides alternative combination products based on K-opioid receptor agonists. These combination products unexpectedly induced loss of consciousness, and were able to achieve and maintain GA. Furthermore, the combination products suppressed pain perception without the need of a μ-opioid receptor agonist. The combination of Salvinorin A, a selective κ-opioid receptor agonist, with Diazepam or Medetomidine surprisingly led to rapid consciousness, deep analgesia and movement suppression. This combination was found to effectively induce and maintain a state of general anesthesia.